Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
about
Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment ConsiderationsRoles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BISerum TFF3 may be a pharamcodynamic marker of responses to chemotherapy in gastrointestinal cancers.In Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer.Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo.Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.PDZK1 prevents neointima formation via suppression of breakpoint cluster region kinase in vascular smooth muscle.Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples.A monoclonal antibody against a potential cancer biomarker, human ubiquitin-conjugating enzyme E2Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer.Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumTwo novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.The role of hormonal factors and endocrine therapy in ovarian cancer.Hormone response in ovarian cancer: time to reconsider as a clinical target?Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters.Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface.Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk.Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.Endocrine therapy in epithelial ovarian cancer.Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells.Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells.TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.Exploration of global gene expression changes during the estrous cycle in equine endometrium.TRAP1 Regulation of Cancer Metabolism: Dual Role as Oncogene or Tumor Suppressor.Shift from androgen to estrogen action causes abdominal muscle fibrosis, atrophy, and inguinal hernia in a transgenic male mouse model
P2860
Q26751021-D5CDDC07-ABC6-4DD6-B5EF-E748842A1F27Q33688934-C95D97C3-4FAD-4F1B-A387-9C7868176C69Q33767978-73C4B203-78DD-4F27-AED9-61ED16BD5810Q33905866-19F4756B-27B6-450B-813D-F0CDBFF12CC6Q34021008-5B666B3E-080D-4B68-B49E-15C37A469058Q34048134-DEF3CF72-6C60-4E32-B07F-FD4FB5A2B9E7Q34531044-1C1EDFAA-71CB-4699-A458-53F5242CEAEDQ34579904-9EED7A8D-5B58-4779-B5B2-53023C871DFFQ35606603-A329B97D-DD39-4D87-8D65-8890B4C67D56Q35772988-D2689D4B-3BD7-424B-B413-B5940C73DA10Q36066046-1B226319-1D00-43E2-BA62-6F807449A156Q36202508-5CE2064B-46BC-4D46-8711-CB68EEEDF697Q36498614-1373F5E2-86BD-4F8C-BBBB-F0B752225A25Q36699730-73EDA937-460E-4021-A7F1-4A6B1EF31085Q36936727-486B43C0-3BB7-4D18-85E6-F80F16E33CBFQ36966197-D9F99865-1CB2-4988-B6D8-378F92385F4BQ37287502-60FAB291-A01B-4A90-A91B-2872A53BBA55Q37353982-200E4650-251F-4690-9BBB-0369E544E50BQ37417991-82F7997F-BA26-4451-A375-7BDC30E28553Q37688456-8CF771A2-F3A2-4F29-ACCD-02F4D8F4CB23Q38845261-54B378DD-F768-4897-9136-C97A0706E783Q39028384-4A5B67A0-C5EB-4BAD-B899-520D17BAB9D4Q39038223-DE86DF5E-B651-4455-90F7-FEA8F93A1CDFQ39183133-2A4785C2-94CE-4708-9EEC-D5A3FBC75FF4Q39555908-47038BD5-2703-45AA-824E-43CDD549848BQ39697036-D368C5BB-6423-4846-961E-53E7A8D3852EQ51021273-E97D35C9-8899-41E5-B594-BC8A32FE7E46Q53138981-2F0FABFA-62EE-45C1-BE1B-031695F21B73Q53698115-9FC67300-FE66-4D10-B778-0896F09D716BQ57460030-A03524E9-F749-4C9D-A1F2-A3B4F105D6CD
P2860
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Estrogen-regulated gene expres ...... patients with ovarian cancer.
@en
type
label
Estrogen-regulated gene expres ...... patients with ovarian cancer.
@en
prefLabel
Estrogen-regulated gene expres ...... patients with ovarian cancer.
@en
P2093
P1433
P1476
Estrogen-regulated gene expres ...... patients with ovarian cancer.
@en
P2093
Alistair R W Williams
David A Cameron
Graeme Walker
John F Smyth
Kenneth MacLeod
Simon P Langdon
P304
P356
10.1016/J.YGYNO.2007.05.009
P407
P577
2007-07-10T00:00:00Z